PURPOSE: MicroRNAs (miRNAs) are endogenously expressed, noncoding, small RNAs that inhibit protein translation through binding to target mRNAs. Recent studies have demonstrated that miRNAs can regulate tumor cell proliferation and migration. MicroRNA-34a (miR-34a), a potential key effector of the p53 tumor-suppressor gene, was studied as a potential tumor suppressor in uveal melanoma. METHODS: Northern blot analysis was performed to detect the expression level of miR-34a in uveal melanoma cells and melanocytes. Subsequently, melanoma cell proliferation and migration were examined by MTS cell proliferation and transwell migration assays, respectively. The target of miR-34a was predicted by bioinformatics and confirmed using a luciferase assay. In addition, expression of c-Met and cell cycle-related proteins was determined by Western blotting and immunofluorescence after the introduction of miR-34a. RESULTS: miR-34a is actively expressed in melanocytes but not in uveal melanoma cells based on Northern blot analysis. Transfection of miR-34a into uveal melanoma cells led to a significant decrease in cell growth and migration. After identification of two putative miR-34a binding sites within the 3' UTR of the human c-Met mRNA, miR-34a was shown to suppress luciferase activity using HEK293 cells with a luciferase reporter construct containing the binding sites. miR-34a was confirmed to downregulate the expression of c-Met protein by Western blotting and immunofluorescence. Furthermore, the introduction of miR-34a downregulated phosphorylated Akt and cell cycle-related proteins. CONCLUSIONS: These results demonstrate that miR-34a acts as a tumor suppressor in uveal melanoma cell proliferation and migration through the downregulation of c-Met.
PURPOSE: MicroRNAs (miRNAs) are endogenously expressed, noncoding, small RNAs that inhibit protein translation through binding to target mRNAs. Recent studies have demonstrated that miRNAs can regulate tumor cell proliferation and migration. MicroRNA-34a (miR-34a), a potential key effector of the p53tumor-suppressor gene, was studied as a potential tumor suppressor in uveal melanoma. METHODS: Northern blot analysis was performed to detect the expression level of miR-34a in uveal melanoma cells and melanocytes. Subsequently, melanoma cell proliferation and migration were examined by MTS cell proliferation and transwell migration assays, respectively. The target of miR-34a was predicted by bioinformatics and confirmed using a luciferase assay. In addition, expression of c-Met and cell cycle-related proteins was determined by Western blotting and immunofluorescence after the introduction of miR-34a. RESULTS:miR-34a is actively expressed in melanocytes but not in uveal melanoma cells based on Northern blot analysis. Transfection of miR-34a into uveal melanoma cells led to a significant decrease in cell growth and migration. After identification of two putative miR-34a binding sites within the 3' UTR of the humanc-Met mRNA, miR-34a was shown to suppress luciferase activity using HEK293 cells with a luciferase reporter construct containing the binding sites. miR-34a was confirmed to downregulate the expression of c-Met protein by Western blotting and immunofluorescence. Furthermore, the introduction of miR-34a downregulated phosphorylated Akt and cell cycle-related proteins. CONCLUSIONS: These results demonstrate that miR-34a acts as a tumor suppressor in uveal melanoma cell proliferation and migration through the downregulation of c-Met.
Authors: Miguel F Segura; Ilana Belitskaya-Lévy; Amy E Rose; Jan Zakrzewski; Avital Gaziel; Douglas Hanniford; Farbod Darvishian; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Iman Osman; Eva Hernando Journal: Clin Cancer Res Date: 2010-02-23 Impact factor: 12.531
Authors: Mark Mackiewicz; Konrad Huppi; Jason J Pitt; Tiffany H Dorsey; Stefan Ambs; Natasha J Caplen Journal: Breast Cancer Res Treat Date: 2011-08-04 Impact factor: 4.872
Authors: Nicholas Latchana; Kelly Regan; J Harrison Howard; Jennifer H Aldrink; Mark A Ranalli; Sara B Peters; Xiaoli Zhang; Alejandro Gru; Philip R O Payne; Lorena P Suarez-Kelly; William E Carson Journal: J Surg Res Date: 2016-07-04 Impact factor: 2.192
Authors: Yunqing Li; Fadila Guessous; Ying Zhang; Charles Dipierro; Benjamin Kefas; Elizabeth Johnson; Lukasz Marcinkiewicz; Jinmai Jiang; Yanzhi Yang; Thomas D Schmittgen; Beatriz Lopes; David Schiff; Benjamin Purow; Roger Abounader Journal: Cancer Res Date: 2009-09-22 Impact factor: 12.701
Authors: Mitchell S Stark; Sonika Tyagi; Derek J Nancarrow; Glen M Boyle; Anthony L Cook; David C Whiteman; Peter G Parsons; Christopher Schmidt; Richard A Sturm; Nicholas K Hayward Journal: PLoS One Date: 2010-03-12 Impact factor: 3.240
Authors: Drazen M Jukic; Uma N M Rao; Lori Kelly; Jihad S Skaf; Laura M Drogowski; John M Kirkwood; Monica C Panelli Journal: J Transl Med Date: 2010-03-19 Impact factor: 5.531